[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Strasbourg, France\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":592},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,250,0,25,[9,48,69,98,124,148,171,194,214,237,262,283,306,327,353,379,399,418,438,462,480,504,531,551,570],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100567108","chronic-anergic-depression-identification---magnetic-resonance-imaging-exploration-in-the-elderly-of-traits-related-to-onset-100567108",false,"NCT06663891","Chronic Anergic Depression IDentification - Magnetic Resonance Imaging Exploration in the Elderly of Traits Related to Onset","Identification of Trait Markers Differentiating Late-onset Depression From Early-onset Depression in Chronic Anergic Depression in the Elderly","CAnD'ID-METRO","Inclusion Criteria:\n\n* Patient aged 60 (inclusive) to 90 years (exclusive)\n* Patient presenting with active or remitted anergic depression according to the operational criteria of the \"Chronic Anergic Depression Open Trial\" (1) confirmed by two psychiatrists involved in the study:\n\n  * Early Onset Depression (EOD) group: with at least one history of depression before age 60\n  * Late Onset Depression (LOD) group: no history of depression before age 60\n* Patient able to understand the objectives\u002Frisks of the research and give informed consent\n* Patient affiliated to a health insurance social protection scheme, beneficiary or dependent\n\nExclusion Criteria:\n\n* Contraindication to an MRI scan (including claustrophobia)\\*\n* Psychiatric or organic comorbidity that may interfere with the interpretation of results (e.g. neurovascular disease, psychotic disorder, proven neurodegenerative disease)\n* Concomitant treatment that may interfere with the interpretation of results (e.g. interferons, corticosteroids)\n* Patient in exclusion period (from a previous or current study)\n* Current protective measure (curatorship, guardianship)\n* Patient under legal protection \\* presence of non-removable ferromagnetic foreign body, prosthesis, pacemaker, defibrillator, neurostimulation device, medications delivered by an implanted pump, vascular clip or stent, heart valve or ventricular shunt, implanted device incompatible with 3 Tesla MRI exam, claustrophobia, epilepsy","ALL","60 Years","90 Years",{"count":22,"type":23},50,"ESTIMATED","INTERVENTIONAL",[26],"NA","Depression in the elderly, or \"late life depression\" (LLD), is often considered to be homogeneous, legitimizing standardized treatment. Yet the literature suggests that there are different forms of LLD, with different pathophysiology, course and treatment.\n\nOur experience has led us to identify an \"anergic\" form, marked by adynamia and anhedonia (anergic depression, AnD). Highly represented among LLDs, it readily resists the usual antidepressants, so that its course is often chronic. Thanks to the \"Chronic Anergic Depression Open Trial\", the investigators were able to show that AnD responds to dopaminergic (DA) molecules. Therefore the invastigators hypothesized a pathophysiology linked to dysfunction of the mesolimbic DA system.\n\nHowever, not all patients would present the same form: two subgroups could be isolated, each contributing equally. The first corresponds to patients for whom the episode is a recurrence, the so-called \"early onset depression\" (EOD). The first episode occurs at 34 ±16 years of age and is frequently associated with a personality disorder (73%). The index episode usually lasts 6 ±3 years and is typically associated with anxiety (96%).\n\nThe second group corresponds to the onset of primary depression after the age of 60, known as \"late onset depression\" (LOD). The index episode occurs at around 71 ±6 years of age, in people with no premorbid personality disorders. The episode is shorter (3 ±1 years) and anxiety is frequent (75%) but less marked. These patients showed a high propensity for a course compatible with synucleinopathies, but often less rapid than that of the classic forms of these diseases.\n\nThe investigators hypothesize that within AnD, EOD and LOD present different pathophysiologies, and that this difference is observable on functional magnetic resonance imaging (MRI): LOD patients should present a greater reduction in functional connectivity in the mesolimbic system. The investigators make the subsidiary hypothesis that LODs also show a structural alteration observable with other types of MRI measurements, i.e. multiparametric imaging.",[29],"Late Life Depression",[31,32,33,34],"Late life depression neuroimaging,","connectivity,","apathy,","dopaminergic system","RECRUITING","2026-08-20",{"date":38,"type":39},"2026-08-21","ACTUAL",{"date":41,"type":39},"2025-07-17",{"date":43,"type":23},"2027-03-01",{"name":45,"class":46},"University Hospital, Strasbourg, France","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":24,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":47},"100560405","combined-genome-and-rna-sequencing-for-genetic-diagnosis-of-parkinsonism-100560405","NCT06576713","Combined Genome and RNA Sequencing for Genetic Diagnosis of Parkinsonism","Identification of the Missing Genetic Causes of Parkinsonian Syndromes: a Combined Approach by Genome and RNA Sequencing","ParkOmic","Inclusion Criteria:\n\n* Extrapyramidal syndrome beginning before or at the age of 40 or associated with a family history:\n* Dopaminergic denervation proven by ioflupane brain scintigraphy (DaTscan®)\n* DNAs from both asymptomatic parents available in biobank\n* Subject affiliated to a social protection health insurance scheme or beneficiary or beneficiary\n* Subject able to understand the objectives and risks related to the research and to give dated and signed informed consent\n\nExclusion Criteria:\n\n* \\- Contraindication for performing a superficial skin biopsy provided for by the protocol\n* Molecular cause of parkinsonism previously identified\n* Absence of prior genetic exploration by high-throughput DNA sequencing\n* Patient with late-onset sporadic parkinsonian syndrome (\\> 40 years) without family history\n* Patient with Parkinson's syndrome associated with a specific diagnosis (genetic or non-genetic pathology: exposure to neuroleptics, toxic origin)\n* Impossibility of providing the subject with informed information\n* Subject under judicial protection\n* Subject under guardianship or curatorship","18 Years",{"count":58,"type":23},14,[26],"Despite the increasing availability and advances in the analysis of high-throughput DNA sequencing, the majority of patients with early-onset or familial parkinsonism remain without a molecular diagnosis.\n\nStudying the genetic forms of parkinsonian syndromes presents numerous clinical, scientific and therapeutic interests. In clinical practice, identifying the genetic cause in a patient allow to provide genetic counseling and estimate the risk of recurrence in their relatives. Establishing correlations between the genotype and phenotype of patients with genetically determined parkinsonism, allow to better anticipate the evolution of the disease, or even to highlight biomarkers during the presymptomatic phases. Finally, the proteins encoded by the genes implicated in familial parkinsonism represent potential therapeutic targets likely to be modulated by neuroprotective pharmacological agents, even in sporadic Parkinson's disease.\n\nIn this work,investigators aimed at elucidating the missing genetic causes of parkinsonism through the application of combined RNA and whole genome sequencing.",[62],"Parkinson's Disease",{"date":38,"type":39},{"date":65,"type":39},"2025-01-14",{"date":67,"type":23},"2027-01-01",{"name":45,"class":46},{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":18,"minAge":56,"maxAge":19,"enrollmentInfo":78,"targetDuration":4,"studyType":24,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":47},"100503225","phase-3-eeg-mri-imaging-of-methylphenidate-effects-in-adult-adhd-and-attentional-symptoms-in-mood-disorders-100503225","NCT05832489","EEG-MRI Imaging of Methylphenidate Effects in Adult ADHD and Attentional Symptoms in Mood Disorders","EEG-MRI Study of the Effect of Methylphenidate on Neural Mechanisms in Adult Patients With ADHD With or Without Mood Disorders: a Randomized Controlled Trial Versus Placebo","ImAteM-TDA","Inclusion criteria common to all groups:\n\n* Subject (male or female) aged 18 to 60 years old\n* Subject affiliated to a social protection health insurance scheme\n* Subject capable of understanding the objectives and risks of the research and of providing dated and signed informed consent\n* Subject having been informed of the results of the prior medical examination\n* For a woman of childbearing age: negative blood pregnancy test and effective contraception throughout the study (intrauterine device, sterilization, estro-progestogen or progestogen per os, injectable or in the form of an implant or ring) and refusal to perform a pregnancy test before each MRI)\n\nInclusion criteria for Group A: ADHD patients without associated mood disorder (ADHD-P)\n\n* Diagnosis of ADHD according to DSM-5 (in particular criterion B: presence of symptoms before the age of 12 years) NB: the diagnosis was not necessarily made at this age.\n* Subject with or without methylphenidate treatment\n\nInclusion criteria for Group B: Patients with attention deficit disorder due to\u002Faccentuated by mood disorders (ADHD-MD)\n\n* Association of ADHD symptoms with attentional disorders according to the combination of the following criteria :\n* Diagnosis of Recurrent Depressive Disorder or Bipolar Disorder according to DSM-5\n* Currently euthymic, i.e. a QIDS-16SC depression score \\\u003C 6 and a YRMS mania score \\\u003C 6, and clinically stabilized for at least 6 weeks prior to inclusion (stable and off-acute treatment). NB: for ISQ item 10 (concentration\u002Fdecision making, score decision making only)\n* DSM-5 Adult ADHD Criteria A (at least 5 symptoms of inattention and\u002For hyperactivity\u002Fimpulsivity)\n* Absence of Criterion D during childhood, adolescence and before mood disorders (i.e., no significant impact with reduced quality of social, academic or occupational functioning)\n* Presence of Criterion D at present (symptoms have a significant impact with a reduction in the quality of social, academic or professional functioning)\n* Subject with or without approved mood disorder treatment: Mood stabilizers (lithium, valproate, lamotrigine); antidepressants (SSRIs, IRSNa ≤60mg\u002Fj of venlafaxine and ≤60mg\u002Fj of duloxetine); benzodiazepines in stable doses for more than a month.\n* Subject with or without methylphenidate treatment\n\nInclusion criteria for Group C: healthy subjects control\n\n\\- Subject with no psychiatric or neurological history\n\nExclusion criteria common to all groups\n\n* Subjects with contraindication to methylphenidate :\n\n  * hypersensitivity to the active substance,\n  * glaucoma,\n  * pheochromocytoma,\n  * treatment with other indirect sympathomimetics or alpha sympathomimetics (oral and\u002For nasal routes), irreversible MAOIs\n  * Hyperthyroidism or thyrotoxicosis,\n  * Pre-existing cardiovascular disorders including severe hypertension, heart failure, occlusive arterial disease, angina pectoris, congenital heart disease with hemodynamic impact, cardiomyopathy, myocardial infarction, arrhythmias and potentially life-threatening ductopathies (disorders caused by ion channel dysfunction),\n  * Pre-existing cerebrovascular disorders, brain aneurysms, vascular abnormalities including vasculitis or stroke,\n  * wheat allergy (other than celiac disease)\n* Diagnosis or history of severe depression, anorexia nervosa or anorexic disorder, suicidal tendencies, psychotic symptoms, severe mood disorders, mania, schizophrenia, psychopathic or borderline personality disorder.\n* Diagnosis or history of episodic and severe (type 1) (and poorly controlled) bipolar (affective) disorder.\n* Subjectis with contraindication to performing an MRI: presence of non-removable ferromagnetic body, prosthesis, pacemaker, medication delivered by an implanted pump, vascular clip or stent, heart valve or ventricular shunt\n* History that may affect brain anatomy or be related to an abnormality (neonatal suffering, neurosurgical operation, comitiality, stroke, head injury with unconsciousness of more than 15 minutes and mental retardation)\n* History that may affect brain function (general anaesthesia or ECT within 3 months prior to inclusion)\n* Substance Use Disorder as per DSM-5 criteria (except tobacco)\n* Pregnant women or, in women of childbearing age and ability (non-sterile), lack of effective contraception\n* Breastfeeding women\n* Severe or unstable somatic pathology.\n* Subject deprived of liberty, or in care under restraint\n* Subject under safeguard of justice\n* Incompetent subject (subject to a legal protection measure: curatorship, guardianship, future protection mandate, family habilitation)\n* Impossibility to give informed information about the subject (subject in an emergency situation, difficulties in understanding the subject, ...)\n* Subject in exclusion period defined by another protocol in progress\n\nExclusion criteria for Group A: ADHD patients without associated mood disorder (ADHD-P)\n\n* Current Mood Disorder\n* History of bipolar disorder in a first-degree relative\n* Taking unauthorized psychotropic drugs: all antidepressants, antipsychotics, sedative antihistamines, regular hypnotics, benzodiazepines in unstable doses.\n\nExclusion criteria for Group B: Patients with attention deficit disorder due to\u002Faccentuated by mood disorders (ADHD-MD)\n\n* Acute phase of mood disorder defined by scores a depression score in the QIDS-16SC ≥ 6 and a mania score in the YRMS ≥ 6. NB: for ISQ item 10 (concentration\u002Fdecision making, score decision making only).\n* Use of unauthorized psychotropic drugs including antipsychotics, sedative antihistamines, high-dose IRSNa (\\>150mg\u002Fd venlafaxine and \\>60mg\u002Fd duloxetine), MAOIs, tricyclic antidepressants, benzodiazepines in unstable doses.",true,{"count":79,"type":23},80,[81],"PHASE3","Attention Deficit Hyperactivity Disorder (ADHD) in adults is a common psychiatric disorder, with important consequences in terms of quality of life, mental health (associated disorders and poorer response to treatment), family life, risk of accidents; with a consequent cost for society.\n\nAdult ADHD is frequently associated with psychiatric co-morbidities, and notably associated with mood disorders (major depressive disorder or bipolar disorder) in about 50% of cases.\n\nThe diagnosis of ADHD in adults is made in patients with an attentional complaint (pure ADHD or ADHD-P), but also very often in the management of a comorbid mood disorder (ADHD associated with mood disorder, or ADHD-MD). In this case, the ADHD had no impact during childhood and adolescence.\n\nMedication management is well established for ADHD-P, and medication is based on methylphenidate, which has a rapid and significant effect on attentional symptoms and impulsivity. However, in the case of ADHD-HD, there is little evidence of treatment efficacy and the mechanisms of action of methylphenidate at the brain level are poorly understood.\n\nThe aim of the study is to determine the neural mechanisms of the effect of methylphenidate, using functional MRI and EEG, in ADHD-P and ADHD-HD patients, and to compare them to healthy subjects. A single dose allows us to observe effects that are then persistent with repeated doses. The aim is to determine, by means of a biomarker, whether methylphenidate treatment responds to the same mechanisms in the different groups and would be relevant in ADHD-P as in ADHD-HD.\n\nMain objective:\n\nTo determine whether methylphenidate impacts differently on brain circuits associated with cognitive functions in the two clinical populations studied (adult ADHD patients and patients with post mood disorder attentional deficit) and in comparison to controls.\n\nSecondary objectives:\n\n1. To determine the effect of methylphenidate on baseline brain flow in the two clinical populations and in controls (healthy subjects).\n2. To determine whether methylphenidate has a different impact on cognitive performance in the two clinical populations studied and in comparison to controls (healthy subjects).\n3. To confirm the effect of methylphenidate on the maintenance of cortical arousal.\n4. To distinguish the brain networks impacted by methylphenidate (maintenance of attention or inhibition) with MRI and EEG.",[84,85],"Adult ADHD","Adult-onset ADHD With Mood Disorder",[84,87,88,89,90,91],"Sustained attention","fMRI","EEG","Pharmacoimaging","Methylphenidate",{"date":38,"type":39},{"date":94,"type":39},"2024-02-26",{"date":96,"type":23},"2027-05",{"name":45,"class":46},{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":12,"sex":105,"minAge":56,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":24,"phases":108,"briefSummary":109,"conditions":110,"keywords":113,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":47},"100391279","evaluation-of-a-new-predictive-test-of-preterm-birth-in-case-of-threatened-preterm-labor-100391279","NCT04374916","Evaluation of a New Predictive Test of Preterm Birth in Case of Threatened Preterm Labor","PREMAQUICK","Inclusion Criteria:\n\n* Patient aged \\> 18 years (with no upper age limit)\n* Patient affiliated to a social security health regime\n* Between 24 and 33 + 6 weeks of gestation (amenorrhea)\n* Singleton pregnancy\n* Patient with a TPL: Uterine contractions during the last 24 hours felt by the patient, painful or not, and cervix less than or equal to 25 mm on endovaginal ultrasound\n* Having signed an informed consent form\n\nExclusion Criteria:\n\n* Twin pregnancy\n* Sexual intercourse less than 24 hours from inclusion\n* Cervical cerclage\n* Abundant metrorrhagia\n* Premature rupture of membranes\n* Pre-eclampsia\n* Congenital malformation\n* Presence of a placenta previa\n* Pelvic examination in the previous 24 hours (compared to inclusion)\n* Patient under guardianship, curatorship or safeguard of justice\n* Persons deprived of their liberty by judicial or administrative decision\n* Persons under psychiatric care under duress","FEMALE",{"count":107,"type":23},200,[26],"Threatened preterm labor (TPL) is defined by cervical changes and regular and painful uterine contractions occurring between 24 and 36 + 6 weeks of gestation that may or may not lead to premature labor and delivery. There is no reliable way to predict preterm delivery.\n\nThe study's hypothesis is that the Premaquick® test can improve the prediction of preterm delivery.\n\nThe investigators also want to compare this test with the Partosure® (Placental alpha microglobulin-1) test.",[111,112],"Threatened Preterm Labor","Preterm Delivery",[114,112,115,116],"Threatened preterm labor","Preterm birth","IGFBP-1","2026-08-19",{"date":38,"type":39},{"date":120,"type":39},"2020-08-11",{"date":122,"type":23},"2026-09",{"name":45,"class":46},{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":24,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":47},"100614005","clinical-study-evaluating-the-effect-of-virtual-reality-on-reducing-patients-anxiety-during-wisdom-teeth-extraction-100614005","NCT07273968","Clinical Study Evaluating the Effect of Virtual Reality on Reducing Patients' Anxiety During Wisdom Teeth Extraction","Clinical Study Evaluating the Effect of Virtual Reality on Reducing Anxiety in Patients Undergoing Wisdom Teeth Extraction","SEREIN","Inclusion criteria:\n\n* Age 18-65\n* Indication for extraction of 4 wisdom teeth or ≥2 mandibular wisdom teeth\n* ASA I-II\n* Written informed consent.\n\nExclusion criteria:\n\n* Visual\u002Fhearing impairment\n* Psychiatric disorders or psychotropics (\\\u003C8 weeks)\n* Claustrophobia\n* Heavy smoking \\>10 cig\u002Fday\n* Previous radiotherapy (jaw)\n* ASA III-IV\n* Pregnancy\n* Antithrombotic therapy\n* Chemotherapy\n* Bisphosphonates\n* Uncontrolled diabetes\n* Severe anxiety requiring GA or pharmacological sedation\n* No health insurance affiliation.","65 Years",{"count":134,"type":23},60,[26],"Dental anxiety is common during third molar extractions and may exacerbate pain perception. Local anesthesia does not prevent exposure to stress-inducing stimuli. Virtual reality (VR) combined with hypnotic scripts (HypnoVR®) provides immersive multisensory distraction. This study tests whether VR reduces perioperative anxiety and postoperative pain compared to local anesthesia alone.",[138,139,140],"Dental Anxiety","Third Molar Extraction","Oral Surgery","2026-08-18",{"date":36,"type":39},{"date":144,"type":39},"2026-04-10",{"date":146,"type":23},"2027-09-01",{"name":45,"class":46},{"id":149,"slug":150,"hasResults":12,"nctId":151,"briefTitle":152,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":165,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":47},"100612253","characterization-of-autoreactive-b-lymphocytes-in-autoimmune-diseases-and-immune-deficiencies-100612253","NCT07251179","Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies","AutoB-Tetramer","Inclusion Criteria:\n\n* Patients aged between 18 and 70\n* Patients for whom at least one of the following conditions has been confirmed:\n* Systemic lupus erythematosus meeting the 2019 ACR\u002FEULAR classification criteria.\n* Systemic scleroderma meeting the 2013 ACR\u002FEULAR classification criteria. ANCA-associated vasculitis according to the 2022 EULAR\u002FACR classification criteria.\n* Antiphospholipid syndrome according to the 2023 ACR\u002FEULAR criteria.\n* Primary immunodeficiencies according to IUIS criteria.\n* Patients capable of understanding the objectives of the research.\n* Patients affiliated with a social security health insurance scheme (beneficiary or dependant).\n* Patients who have signed and dated the informed consent form for non-identifying genetic testing.\n\nExclusion Criteria:\n\n* Patient refusing to participate in the study\n* Patient in a period of exclusion (determined by a previous or ongoing study) Inability to provide the subject with informed consent (in an emergency or immediate life-threatening situation, difficulties in understanding the subject, etc.)\n* Patient under legal protection\n* Patient under guardianship or conservatorship","70 Years",{"count":107,"type":23},"OBSERVATIONAL","Autoimmune diseases (AID), whether systemic or organ-specific, affect approximately one in ten people, and their prevalence continues to increase. Many AIDs are linked to the emergence of autoreactive B cells (BCs) directed against components of the self. In healthy individuals, these autoreactive B cells are counter-selected or regulated before reaching the antibody-secreting cell compartment. However, in predisposed individuals, a breakdown in B cell tolerance can occur, leading to the formation of autoantibodies with devastating consequences, such as the emergence of systemic lupus erythematosus (SLE), rheumatoid arthritis, and vasculitis. B-cell depletion is often beneficial in these patients, but paradoxically, therapies targeting B cells are not always effective. Furthermore, B cell depletion via LB-specific antibodies (anti-CD20) or treatment with CD19 chimeric antigen receptor T cells (CAR T) leads to complete and prolonged depression of the entire B compartment without targeting the LB population responsible for the onset of the disease. To date, two pitfalls in studies of human autoreactive LBs often complicate the interpretation of results:\n\ni) the difficulty of identifying autoreactive LBs among all LBs, ii) demonstrating the pathogenicity of autoreactive B lymphocytes when they can be identified individually. We propose to quantify and phenotype these autoreactive\u002Fpathogenic B cells using high-throughput flow cytometry in several clinical situations.",[160,161,162,163,164],"Systemic Lupus Erythematosus","Systemic Scleroderma","ANCA-associated Vasculitis","Antiphospholipid Syndrome","Primary Immunodeficiencies",{"date":36,"type":39},{"date":167,"type":39},"2026-01-20",{"date":169,"type":23},"2031-12-31",{"name":45,"class":46},{"id":172,"slug":173,"hasResults":12,"nctId":174,"briefTitle":175,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":24,"phases":181,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":187,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":47},"100609401","phase-2-phase-iib-multicenter-randomized-controlled-trial-evaluating-the-efficacy-of-sivelestat-in-patients-with-septic-coagulopathy-100609401","NCT07214103","Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy","SivelSep","Inclusion Criteria:\n\n* Adults aged 18 to 85 years\n* Patient (male or female) admitted to the ICU with:\n\n  * Septic shock defined by Sepsis-3 criteria: acute, life-threatening organ dysfunction related to a suspected or confirmed infection, requiring vasopressor support to maintain a mean arterial pressure ≥ 65 mmHg and a serum lactate level \\> 2 mmol\u002FL despite adequate fluid resuscitation.\n  * Coagulopathy defined by a SIC score ≥ 4 points.\n* Randomization within 12 hours after the diagnosis of coagulopathy (positive SIC score).\n* Patient affiliated with a national health insurance system.\n* Written informed consent: freely given, dated, and signed.\n\n  * By the patient\n  * Or by a legal representative if the patient is unable to provide consent.\n  * Or through an emergency inclusion procedure if the patient is unable to consent and no family member is available\n\nExclusion Criteria:\n\n* History of hypersensitivity reaction to Sivelestat (the only contraindication for Sivelestat)\n* Patient weight \\> 100 kg\n* Severe chronic liver disease (Child-Pugh C)\n* Contraindication to the use of unfractionated heparin\n* Moribund patient at the time of randomization\n* Limitation of active therapeutic interventions at the time of study inclusion\n* Under legal protection (guardianship, curatorship, or legal safeguard)\n* Pregnancy or breastfeeding\n* Participation in another interventional drug clinical trial","85 Years",{"count":180,"type":23},120,[182],"PHASE2","Sepsis-induced disseminated intravascular coagulation (DIC) is a severe complication occurring in one-third of patients with septic shock, for which no specific treatment currently exists. It results from excessive systemic activation of coagulation and impaired fibrinolysis, leading to the development of disseminated microthromboses. We have recently demonstrated: 1) the contribution of NETs to the hypercoagulability observed in DIC, and 2) the role of neutrophil elastase-bound to NET DNA-in degrading plasminogen, a key factor limiting fibrinolysis and thus preventing the lysis of microthrombi in DIC.\n\nSivelestat is a neutrophil elastase inhibitor used in Japan for the treatment of acute respiratory distress syndrome (ARDS). It has the potential to inhibit: 1) neutrophil activation and the release of inflammatory mediators, and 2) plasminogen degradation, which drives fibrinolytic failure. A recent meta-analysis including 2,050 patients across 15 studies showed that Sivelestat reduced ARDS patient mortality at day 28-30 (RR = 0.81, 95% CI = 0.66-0.98, p = 0.03), decreased mechanical ventilation duration and ICU length of stay, and improved oxygenation.\n\nWe propose to conduct a multicenter, double-blind, placebo-controlled phase IIb trial evaluating the efficacy of Sivelestat in restoring fibrinolysis in patients with septic shock complicated by coagulopathy, defined by a positive SIC score (≥ 4 points).",[185,186],"Septic Shock","Coagulopathy","NOT_YET_RECRUITING",{"date":36,"type":39},{"date":190,"type":23},"2027-08-01",{"date":192,"type":23},"2032-12-31",{"name":45,"class":46},{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":132,"enrollmentInfo":202,"targetDuration":4,"studyType":24,"phases":204,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":208,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":47},"100604229","personalized-metacognitive-training-for-psychosis-a-randomized-controlled-trial-100604229","NCT07146802","Personalized Metacognitive Training for Psychosis: A Randomized Controlled Trial","Towards a Personalized Medicine Approach to Psychological Treatment for Psychosis","PERMEPSY","Inclusion Criteria:\n\n* Adults, 18 - 65 years of age.\n* Patient affiliated to health insurance\n* Inpatients and outpatients with DSM-5 diagnosis of schizophrenia spectrum disorder.\n* Presence of positive symptoms at inclusion (PANSS delusions, suspiciousness or grandiosity ≥3).\n* Stable condition with no expected changes in medication or symptoms during the last 3 months (information from clinical services, note that stable condition includes lack of suicidality).\n* Patient providing informed consent.\n\nExclusion Criteria:\n\n* Having received MCT in the previous year.\n* Neurological disorder, or severe medical condition other than psychosis\n* A score above 5 in the \"Hostility\" and the \"Suspiciousness\" items of the PANSS Positive subscale (to preserve group dynamics).\n* Patient considered by his psychiatrist to be at serious risk of harm to self or others (e.g. previous aggressive or suicidal behaviors)\n* Patient in an exclusion period defined by another research protocol\n* Patient involved in another Investigational Medicinal Product trial\n* Patient under guardianship (i.e. French \"tutelle\")\n* Patients deprived of freedom because of a judicial measure.",{"count":203,"type":23},51,[26],"This study aims to compare the efficacy of classical Metacognitive Training (MCT) and personalized Metacognitive Training (P-MCT) for individuals with psychosis. MCT is a psychoeducational program derived from cognitive-behavioral therapy (CBT) that targets cognitive biases associated with psychotic symptoms. The goal is to assess which intervention is more effective to improve the overall functioning of individuals with psychosis. The study will use machine learning to personalize the treatment approach and evaluate its impact on clinical symptoms, cognitive functions, and quality of life.",[207],"Schizophrenia Spectrum Disorder",{"date":36,"type":39},{"date":210,"type":39},"2026-04-03",{"date":212,"type":23},"2027-04-01",{"name":45,"class":46},{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":24,"phases":224,"briefSummary":225,"conditions":226,"keywords":228,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":231,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":47},"100603810","empagliflozins-microcirculatory-effects-in-cardiogenic-shock-an-ancillary-pilot-study-of-the-empashock-trial-100603810","NCT07141355","Empagliflozin's Microcirculatory Effects in Cardiogenic Shock: an Ancillary Pilot Study of the EMPASHOCK Trial","Microcirculatory Effects of Empagliflozin in Patients With Cardiogenic Shock: an Ancillary Pilot Study of the EMPASHOCK Trial","EMPAmicroSHOCK","Inclusion Criteria:\n\n* Patient included in the main EMPASHOCK study\n* Patient has signed a consent form for the ancillary study\n* Patient is over 18 years old\n* Hospitalized in the Intensive Care Unit for cardiogenic shock\\*\n* Has been or is on catecholamines for at least 12 hours for the treatment of cardiogenic shock\\*\\*\n* Patient has the ability to take tablets orally\n* Person is affiliated with or a beneficiary of a social security system\n\nExclusion Criteria:\n\n* • GFR \\\u003C 20 ml\u002Fmin\u002F1.73m²\n\n  * Chronic dialysis\n  * Patient on SGLT2 inhibitors prior to ICU admission\n  * Known allergy to SGLT2 inhibitors or any of their excipients (in particular, patients with hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption syndrome).\n  * Patient on lithium\n  * Patient with type 1 diabetes\n  * Patient in shock due to another cause or moribund patient (IGS 2 \\> 90)\n  * Cardiogenic shock cases excluded in the EMPASHOCK study: a. Heart transplant recipient or on a transplant list. b. Peripartum, adrenergic, valvular, restrictive, or post-embolic cardiomyopathy. c. Related to cardiotropic drug intoxication. d. Secondary to cardiac arrest where the patient remains comatose before inclusion.\n  * Woman of childbearing age without effective contraception\n  * Person referred to in Articles 10, 31, 32, 33, and 34 of EU Regulation 536\u002F2014, specifically:\n* Pregnant woman, woman in labor, or breastfeeding mother\n* Minor person (not emancipated)\n* Adult person subject to a legal protection measure (guardianship, curatorship, legal safeguard)",{"count":223,"type":23},24,[26],"Despite advancements in treatment, the mortality rate for cardiogenic shock (CS) remains high at around 50%. The EMPULSE-HF trial showed that early introduction of empagliflozin in stabilized patients with acute heart failure led to a composite benefit in mortality, rehospitalization, and quality of life.\n\nGrowing evidence suggests that cardiogenic shock isn't just a problem of systemic macrocirculation (blood pressure, cardiac output). It also involves significant abnormalities in the systemic microcirculation. In fact, these microcirculatory parameters have proven to be better predictors of patient outcomes than traditional macrocirculatory measures.\n\nGiven its known vasculo-protective effects on the endothelium, empagliflozin may have a beneficial impact on the microcirculation, potentially explaining its positive effects in cardiogenic shock.\n\nThis study will explore this hypothesis by analyzing the microcirculation in real-time using the CytoCam-IDF imaging videomicroscope and its MicroTools software. The goal is to gain a deeper understanding of how empagliflozin affects the microcirculation during cardiogenic shock.",[227],"Cardiogenic Shock",[227,229,230],"Acute Heart failure","Heart failure",{"date":36,"type":39},{"date":233,"type":39},"2025-12-12",{"date":235,"type":23},"2027-09-30",{"name":45,"class":46},{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":24,"phases":247,"briefSummary":248,"conditions":249,"keywords":253,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":256,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":47},"100598149","cefazolin-antibiotic-prophylaxis-in-ventricular-shunt-surgery-determination-of-cerebrospinal-fluid-concentration-during-valve-implantation-100598149","NCT07067736","Cefazolin Antibiotic Prophylaxis in Ventricular Shunt Surgery: Determination of Cerebrospinal Fluid Concentration During Valve Implantation","Cefazolin Antibiotic Prophylaxis in Ventricular Shunt Surgery: Determination of Cerebrospinal Fluid(CSF) Concentration During Valve Implantation","CC -PIV","Inclusion Criteria:\n\nAge \\>18 years and programmed for a ventricular shunt surgery at the Hautepierre university hospital in Strasbourg.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years old\n* Pregnant women\n* Infected patients\n* Known cefazolin allergy\n* Other molecule used for the antibiotic prophylaxis\n* Guardianship or conservatorship\n* Patients under curative antibiotherapy\n* Non sterile pre operative CSF\n* Refusal to participate",{"count":246,"type":23},15,[26],"The objective is to determine the concentration of cefazolin in the cerebrospinal fluid after a recommended antiobiotic prophylaxis by 2g of cefazolin. Our main hypothesis is that the concentration is insufficient to protect the valve from infections.\n\nThe secondary objective is to compare our results to known pharmacokinetic models of cefazolin diffusion in the literature. If differences are found we would like to search clinical features that could explain it.",[250,251,252],"Hydrocephaly","CSF Shunts","Antibiotic Prophylaxis",[254,255,250],"Antibiotic prophylaxis","CSF shunts",{"date":36,"type":39},{"date":258,"type":39},"2026-02-01",{"date":260,"type":23},"2026-08-30",{"name":45,"class":46},{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":24,"phases":272,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":277,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":47},"100590974","phase-4-comparative-evaluation-of-the-performance-of-different-thromboplastin-reagents-on-prothrombin-time-in-situations-of-isolated-extrinsic-pathway-factor-deficiency-or-liver-damage-100590974","NCT06974396","Comparative Evaluation of the Performance of Different Thromboplastin Reagents on Prothrombin Time in Situations of Isolated Extrinsic Pathway Factor Deficiency or Liver Damage","Comparative Evaluation of the Performance of Different Thromboplastin Reagents on Prothrombin Time and Factorial Assays in Situations of Isolated Extrinsic Pathway Factor Deficiency or Liver Damage","RHEOMICS","Inclusion Criteria:\n\n* Plasma samples from patients addressed to the laboratory of the Strasbourg University Hospital (Strasbourg France) collected and anonymized after completion of the routine testing.\n* Patient with an isolated or combined extrinsic pathway factor deficiency (factor II, V, VII, X).\n\nExclusion Criteria:\n\n* Patient treated with an oral anticoagulant treatment.\n* Patient treated with a parenteral anticoagulant treatment (apart from therapeutic dosages of unfractionated heparin and low molecular weight heparin).",{"count":271,"type":23},20,[273],"PHASE4","Primary purpose :\n\nCompare the sensitivity of several thromboplastin reagents of various origins to prothrombin time and factor II, V, VII and X assays in two different populations of patients :\n\n* Patients with an isolated extrinsic pathway deficiency (acquired or congenital) of factor II or V or VII or X.\n* Patients with an hepatocellular insufficiency generally associated with coagulopathy (with an intensity proportional to the degree of hepatic impairment).\n\nResults of this work should improve knowledge of sensitivity of the screening test represented by the prothrombin time, depending on the origin of thromboplastin reagent used, in relation with coagulopathies mentioned above, as well as the performance of factors II, V, VII, X assays. This work would help to choice of the most suitable reagent for the needs of each hemostasis laboratory\u002Fcenter.",[276],"Hemorrhagic Disorders",{"date":117,"type":39},{"date":279,"type":39},"2025-12-01",{"date":281,"type":23},"2026-12-01",{"name":45,"class":46},{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":24,"phases":293,"briefSummary":294,"conditions":295,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":300,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":47},"100583868","phase-4-eduction-in-immunosuppressive-regimen-among-kidney-transplant-recipients-patients-admitted-to-the-intensive-care-unit-for-septic-shock-andor-acute-respiratory-failure-100583868","NCT06881927","Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and\u002For Acute Respiratory Failure","Reduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and\u002For Acute Respiratory Failure: a Multicenter, Open-label, Phase IIb Randomized Controlled Trial","REDIS","Inclusion Criteria:\n\n* \\- Adult patients, aged 18 years-old and over,\n* Kidney transplant recipients, with transplantation occurring more than 3 months prior to ICU admission\n* Patients admitted to the ICU in the setting of:\n\n  * Septic shock (sepsis requiring vasopressor support, with or without hyperlactatemia),\n  * And\u002For acute respiratory failure of presumed infectious origin (invasive or non-invasive ventilation, FiO2 greater than or equal to 50%),\n* Patients treated with at least an immunosuppressive bitherapy (including steroids, calcineurin inhibitors, mTOR inhibitors, azathioprine, or mycophenolate mofetil),\n* Patients affiliated with a social health insurance protection scheme,\n* Patients able of understanding the objectives and risks related to the research and providing a dated and signed informed consent. If patient is unable to consent: consent from relatives will be searched, and if absent, an emergency procedure will be process.\n* Women of childbearing potential, provided they have a negative blood pregnancy test on the day of the inclusion visit.\n\nExclusion Criteria:\n\n* Minor patients,\n* Patients unable to consent: under legal protection measures, patients deprived of liberty,\n* Kidney transplant recipients treated with Belatacept due to the persistent effect of Belatacept, it is not possible to modulate this treatment in a short term period,\n* Patients with severe chronic graft dysfunction (glomerular filtration rate \\\u003C 20 ml\u002Fmin\u002F1.73m² according to the CKD-EPI formula in the month prior to admission),\n* Transplant renal recipients who have already resumed RRT (hemodialysis or peritoneal dialysis),\n* Multi-organ transplant recipients,\n* Pregnant women",{"count":292,"type":23},212,[273],"Kidney transplantation is the treatment of choice for end-stage chronic kidney disease. Kidney transplantation is at the first rank of solid organ transplantation in France, with 3,376 grafts performed in 2022. Immunosuppressive therapy, required to prevent graft rejection, exposes graft recipients to complications related to decreased immunity, including opportunistic infections and neoplastic complications.\n\nAfter the earlt post-transplantation period, up to 10% of kidney transplant recipients will require admission to the intensive care unit (ICU). The main reasons for admission are septic shock and acute hypoxemic respiratory failure. ICU stay has a significant impact on these patients with a mortality rate reaching 40%, that remains increased even after ICU discharge. Furthermore, an impact on graft function has been demonstrated, with deterioration of graft function in 1\u002F3 of patients, and among those, up to one in two will require resumption of renal replacement therapy (RRT).\n\nAlthough the occurrence of septic shock or acute respiratory failure related to an infection is more common and severe, the optimal management strategy for immunosuppressors is not defined in kidney transplant recipients admitted to the ICU in those settings.\n\nMaintain a high level of immunosuppressive therapies may hinder the recovery from the acute critical condition. Furthermore, these treatments have a narrow therapeutic index; for instance, the management of calcineurin inhibitors is challenging in the ICU due to pharmacodynamic changes associated with the acute situation (distribution volume, organ failure) and the numerous potential drug interactions that carry inherent risks of overdose.\n\nthe investigators hypothesize that a reduction in the level of immunosuppressive treatments could promote recovery in kidney transplant recipients admitted to the ICU for septic shock and\u002For acute hypoxemic respiratory failure, without adversely affecting the risk of rejection or long-term renal prognosis.",[296,297,298,299],"Sepsis and Septic Shock","Acute Respiratory Failure","Kidney Transplant Recipients","Immunosuppressive Agents",{"date":36,"type":39},{"date":302,"type":39},"2026-08-11",{"date":304,"type":23},"2029-08-01",{"name":45,"class":46},{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":77,"sex":18,"minAge":56,"maxAge":19,"enrollmentInfo":313,"targetDuration":4,"studyType":24,"phases":315,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":321,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":47},"100578952","disorders-of-the-sense-of-self-and-physical-activity-100578952","NCT06817980","Disorders of the Sense of Self and Physical Activity","sensdesoi","Inclusion Criteria:\n\n* Criteria common to all participants:\n* Men or women aged 18 to 60 inclusive\n* Subject affiliated to a health insurance scheme, beneficiary or beneficiary's beneficiary\n* Able to understand the aims and risks of the research, and to give informed consent\n* Visual acuity \\> 0.7 on the Freiburg Vision Test (Bach 1996) due to the use of visual equipment\n* BMI (body mass index) \\\u003C 40 (due to cardiovascular risk).\n\nPatient-specific criteria:\n\n* With schizophrenia: criteria for schizophrenia as defined in the DSMV (American Psychiatric Association, 2015)\n* With borderline personality disorder: criteria for borderline personality disorder as defined in the DSMV (American Psychiatric Association, 2015)\n* With vestibular disorders: peripheral vestibular disorders established after otolaryngological examination\n\nExclusion Criteria:\n\n* Criteria common to all participants:\n* Serious or unstabilized somatic pathology (including cardiovascular)\n* History likely to affect cerebral anatomy or to be linked to an abnormality (neonatal suffering, neurosurgical operation, comitiality, stroke...)\n* Presence of joint pain, likely to worsen after exercise\n* \\- Substance use disorders (as defined by DSM-IV TR)\n* 3D vision disorders as measured by the Wirt stereotest (depth perception at a disparity of at least 80'' arc)\n* Movement perception disorders (correct movement discrimination in less than 75% of trials (cf. § V-2.2)\n* History of general anaesthesia in the 3 months preceding the study\n* History of neurological disease\n* Impossibility of giving the subject informed information (subject in emergency situation)\n* Pregnancy declared by patient\n* Breast-feeding\n* Subject in exclusion period (determined by a previous or current study)\n* Subject hospitalized\n* Subject under court protection\n\nExclusion criteria specific to control subjects or patients with vestibular syndrome:\n\nHistory of major psychiatric pathology with current psychotropic medication (i.e., antidepressant, thymoregulator, antipsychotic)",{"count":314,"type":23},168,[26],"Schizophrenia (SZ) patients with metabolic syndrome, patients with vestibular syndrome, and patients with borderline personality disorder, would benefit from physical activity (PA). Yet patient adherence to PA is low, at least in the case of SZ. the investigators work and the literature lead the investigators to consider that, in addition to motivational aspects, disorders of the bodily sense of self could play a role in this lack of adherence. Simply walking involves visual movements related to the self, which must be distinguished from movements in the environment. This means a distinction between self and not-self. Furthermore, these movements are all the more difficult to distinguish as they may also result from the fact that hidden objects become visible as a result of our own movement. In all sense-of-self disorders can themselves affect physical training, and the investigators will measure them in the first stage. In the second stage, the investigators will apply a standard, risk-free PA protocol by walking (3x3 sessions of 30 min). the investigators will test the impact of physical training on the sense of self under different conditions, with one environment minimizing self-related movement, vs. 2 environments with a variable level of enrichment (i.e. hidden objects inducing more or less self-related movement).\n\nAt the end of the protocol, the investigators will offer participants who wish to take part in an ancillary study, i.e. a walking session with mixed-reality goggles. These will superimpose a luminous flux on the periphery of the visual field. According to results obtained in the laboratory, this flux could restore sensory mechanisms impaired in schizophrenia. the investigators will use these glasses in the most difficult condition for the patient, and verify their impact.",[318,319,320],"SCHIZOPHRENIA 1 (Disorder)","Borderline Personality Disorder","Vestibular Syndromes",{"date":36,"type":39},{"date":323,"type":39},"2025-08-11",{"date":325,"type":23},"2028-09-01",{"name":45,"class":46},{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":77,"sex":105,"minAge":335,"maxAge":132,"enrollmentInfo":336,"targetDuration":4,"studyType":24,"phases":337,"briefSummary":338,"conditions":339,"keywords":341,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":347,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":47},"100576666","cerebral-and-cognitive-impact-of-female-professional-soccerpractice-100576666","NCT06788262","Cerebral and Cognitive Impact of Female Professional SoccerPractice","Cerebral and Cognitive Modifications in Retired Female Professional Soccer Players as Compared to Non Exposed to Repeated Cranial Impacts Sportswomen : Transverse Analytic Study","TCFOOT F","Inclusion Criteria:\n\n* Exposed high-level athletes: female professional soccer players at the end of their career (32- years old) playing in France Ligue 1 or 2 exposed to repeated mild head injuries with no history of severe head injury or cerebral\n* Female High-level athletes not exposed to repeated mild head injuries: control group paired for age with female professional soccer players, who have never regularly participated in sports exposing them to head injuries (notably rugby, basketball, handball, American football, hockey, combat sports, etc.) and who have no history of head injury, even mild. Female Professional tennis players or former players will be preferentially recruited.\n\nExclusion Criteria:\n\n* Refusal to be informed of abnormalities on MRI\n* Incapacity to give informed consent or under a legal protection order;\n* History of cerebral concussion including the presence after head shock of one or more of the following signs or symptoms: a period of confusion or disorientation, a period of loss of consciousness of 30 minutes or less, post-traumatic amnesia not exceeding 24 hours\n* History of severe head\u002Fbrain injury;\n* History of neurological or psychiatric disorder;\n* Known cerebral abnormality diagnosed by an imaging exam (CT or MRI);\n* History or regular or occasional consumption of drugs, unweaned active smoking or weaned for less than 1 year, excessive consumption of alcohol (\\> 20 g alcohol per day, evaluated with the formula \"degree of alcohol × volume in cl × 8\u002F1000\"), weaned or not.\n* Usage of medication targeting the central nervous system in the 2 weeks preceding inclusion in the study;\n* Prior history of severe hypertension, diabetes, chronic heart disease, progressive or disabling disease;\n* Contraindication to MRI (claustrophobia, implanted material not compatible with MRI, refusal to be informed of abnormality discovered on MRI)","32 Years",{"count":79,"type":23},[26],"The objective of this study is to evaluate, using MRI, the microstructural consequences and the onset of any cognitive impairment in female professional soccer players at the end of their career, who have experienced repeated minor head injuries. Over the long term, these head injuries could lead to morphological lesions and have an impact on female soccer players' cognitive skills.\n\nThe main evaluation criterion corresponds to the modifications found on MRI in the female professional soccer player group (diffusion tensor, cerebral perfusion, fMRI, cerebral volumetry and cortical thickness, spectroscopy, susceptibility imaging).\n\nThis is an exposure\u002Fnonexposure study assessing the onset of MRI abnormalities (diffusion tensor, cerebral perfusion, fMRI, volumetry and cortical thickness, spectroscopy, susceptibility imaging) in female professional soccer players exposed to repeated mild head injuries, who are either at the end of their career or retired for approximately 10 years, compared to high-level athletes not exposed to head injuries.",[340],"Traumatic Chronic Encephalopathy",[342,343,344,345,346],"soccer","MRI","head traumatism","neuropsychology","traumatic chronic encephalopathy",{"date":36,"type":39},{"date":349,"type":39},"2025-09-13",{"date":351,"type":23},"2027-06-15",{"name":45,"class":46},{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":357,"acronym":358,"eligibilityCriteria":359,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":360,"enrollmentInfo":361,"targetDuration":4,"studyType":24,"phases":363,"briefSummary":364,"conditions":365,"keywords":367,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":47},"100535495","phase-2-a-chronobiological-treatment-combining-evening-melatonin-and-morning-light-therapy-in-idiopathic-hypersomnia-a-prospective-double-bind-randomized-placebo-controlled--trial-100535495","NCT06252571","a Chronobiological Treatment Combining Evening Melatonin and Morning Light Therapy in Idiopathic Hypersomnia: a Prospective, Double Bind, Randomized, Placebo-controlled -Trial","HyperChrono","Inclusion criteria:\n\n* Male or female patient\n* Age ≥ 18 and ≤ 40 years at signature of informed consent form\n* Diagnosed with Idiopathic hypersomnia in a reference\u002Fcompetence center of hypersomnia rare disease network according to ICSD-3 criteria (International classification of sleep disorders) with symptoms lasting since \\>3 months and a total sleep time ≥11hours objectified with a 24h continuous polysomnography realized during the last 12 months\n* Patient with stable medication in the month preceding inclusion and throughout the 10 weeks of participation to the study (except for drugs excluding participation. See list below).\n* Patient able to be compliant with therapy during the required time and at the set schedule.\n* For female patient: effective efficient contraception during the month preceding the inclusion and all along the study\n* Patient who have given written informed consent and are able to understand the objectives and risks associated to the research.\n* Patient affiliated to a social security insurance\n\nExclusion criteria:\n\n1. Criteria related to the underlying disorder (other forms of hypersomnia or sleep disorder)\n\n   * Other primary or secondary hypersomnia (narcolepsy, Kleine-Levin syndrome, post-traumatic hypersomnia, hypersomnia due to medication or substance abuse…)\n   * Other intrinsic sleep disorder according to ICSD-3 criteria (sleep apnea syndrome, restless legs syndrome, insomnia)\n2. Criteria related to pathologies associated with particular risks or consumption of substances that may affect sleep or alertness:\n\n   * Significant psychiatric comorbidities (current severe depressive episode based on the DSM-V criteria, risk of suicide, schizophrenia, bipolar disorder).\n   * Known systemic or severe acute disease (auto-immune diseases…)\n   * Substance \u002F alcohol \u002Fcigarette dependence\n   * Consumption of excessive amounts of caffeine, defined as greater than 600 mg of caffeine of coffee, tea, cola, energy drinks, or other caffeinated beverages per day (1 cup of coffee is approximately 120 mg)\n3. Criteria related to circadian rhythms disturbances\n\n   * Recent transmeridian travel (\\> 2 time zones) within the month before the start of the study\n   * History of shift\u002Fnight work reported within the 6 months preceding the study\n   * Irregular sleep habits (more than 2 hours of delay or advance in bedtime ≥ 3 nights over a week)\n   * Circadian sleep-wake rhythm disorders according to ICSD-3 criteria (advanced or delayed sleep phase syndrome, …)\n4. criteria related to medications (within 1 month prior to study)\n\n   * Sleep promoting drugs (benzodiazepines, z-drugs, sodium oxybate, antihistaminics…)\n   * Wake promoting-drugs (modafinil, pitolisant, methylphenidate, solriamfétol chlorhydrate)\n   * Psychotropics and drugs inducing level 3 sleepiness according to the ANSM (French National Agency for Medicines and Health Products Safety) gradation.\n   * beta-blockers\n   * regular anti-inflammatory drug intake\n   * Exogenous melatonin and\u002For serotonin and or tryptohane (as a drug or a dietary supplement)\n5. Criteria related to relative contra-indications to light therapy\n\n   * Medical history of ophthalmologic diseases causing visual impairment: retinopathy, age-related macular degeneration, macular hole, epiretinal membrane; cataract; optic neuropathy.\n   * On-going medication with a photosensibilizing drug\n   * Photosensitive epilepsia or migraine\n6. Criteria relative to exogenous melatonin administration\n\n   * Prior intolerance to cellulose or exogenous melatonin\n   * Drugs metabolized by CYP1A2 intake within 1 month prior to study: antivitamin K, fluvoxamine, cimetidine, carbamazepine, rifampicin…\n7. Criteria relative to relative contraindications of e-celsius capsules\n\n   * Patient weighting less than 40 kg\n   * Medical history of motility disorders of the gastrointestinal tract and intestinal disorders that can lead to obstruction of the digestive tract, including diverticula, Crohn disease, surgical procedures in the gastrointestinal tract\n   * Known swallowing disorders\n   * In presence of a pacemaker or electro-medical implant.\n   * Patient who has to undergo strong electromagnetic field during the period of use of the system (MRI)\n8. Criteria relative to regulation:\n\n   * Pregnancy, breastfeeding.\n   * Participation in another interventional clinical trial with an exclusion period\n   * Patient with difficulty to read or understand French, or inability to understand the delivered information\n   * Patient in emergency situation\n   * Patient in life-threatening situation\n   * Patient under justice safeguard\n   * Patient under guardianship or limited guardianship\n   * Patient unwilling to refrain from driving and\u002For operating dangerous or hazardous machinery during times of heightened sleepiness or fatigue due to the medication","40 Years",{"count":362,"type":23},72,[182],"Idiopathic hypersomnia (IH) is a chronic disabling disorder characterized by excessive daytime sleepiness (EDS), prolonged nighttime sleep and sleep inertia. IH is a rare disorder, estimated around 0.05%, yet its true prevalence remains unknown. Disease onset occurs most often during young adulthood and is accompanied by severe social, professional and economic impairments, resulting in risk of accident and a loss in patient's quality of life. There are no ANSM (or FDA-) approved treatments for IH symptoms.\n\nIH shares common features with delayed sleep-wake phase disorder (DSWPD) which is a chronic circadian rhythm disorder which occurs as in IH during young adulthood. The combination of evening melatonin and morning bright light therapy is the most effective validated chronotherapy in DSWPD.Moreover, bright light therapy has direct effects and is known to increase daytime alertness and to improve mood.\n\nMelatonin is empirically used in routine clinical practice in patients with IH and French and European recommendations mention melatonin as a possible treatment of sleep inertia in IH.\n\n. Our goal is to bring a proof of concept of a safe therapeutic practice for IH combining exogenous melatonin and bright light therapy in",[366],"Idiopathic Hypersomnia",[368,369,370,371,372],"hypersomnia","light","melatonin","sleep","chronobiotherapy",{"date":36,"type":39},{"date":375,"type":39},"2024-09-07",{"date":377,"type":23},"2027-09-07",{"name":45,"class":46},{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":385,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":24,"phases":389,"briefSummary":390,"conditions":391,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":393,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":47},"100530093","periodontal-microbiota-in-systemic-sclerosis-100530093","NCT06182293","Periodontal Microbiota in Systemic Sclerosis","Impact of Systemic Sclerosis on the Periodontal Microbiota: a Pilot Study","Periomicross","Inclusion Criteria:\n\nCommon inclusion criteria\n\n* Men or women over 18 (adults)\n* Affiliation to a social health insurance plan\n* Subject able to understand the aims and risks of the research and to give signed informed consent form prior to the inclusion in the study\n* More than 12 teeth suitable for evaluation\n\nInclusion criteria for systemic sclerosis patients\n\n* Systemic sclerosis patient with a diagnosis based on the American College of Rheumatology\u002FEuropean League Against Rheumatism criteria (LeRoy et al., 1988 ; van den Hoogen et al., 2013)\n* Diagnosis made during the 2 years preceding study inclusion (early form of the disease)\n\nInclusion criteria for controls\n\n\\- Patient attending the Oral Medicine and Surgery Department from the University Hospital of Strasbourg for a routine dental consultation\n\nExclusion Criteria:\n\n* \\- Subject under court protection\n* Subject under guardianship or curatorship\n* Pregnancy or breastfeeding\n* Impossibility to provide accurate information (emergency situation, comprehension difficulties…)\n* Subject currently involved in another clinical trial or in an exclusion period following participation in another clinical trial\n* Smoking (≥ 10 cigarettes per day)\n* Other associated systemic auto-immune disease (Sjögren syndrome with positive serum anti-SSA and\u002For anti-SSB auto-antibodies, systemic lupus erythematosus…)\n* Progressive chronic illness other than systemic sclerosis\n* Acute infection at inclusion\n* Progressive cancer or cancer diagnosed within 2 years prior to the study\n* Ongoing antibiotic and\u002For antifungal treatment or within 3 months prior to inclusion\n* Probiotics and\u002For prebiotics intake within 3 months prior to inclusion\n* Oral antiseptics within the week before inclusion (chlorhexidin mouthwashes…)\n* Risk of infective endocarditis\n* Corticosteroids ≥10 mg\u002Fday and\u002For proton pump inhibitors within 3 months prior to inclusion\n* Previous hematopoietic stem cell transplantation\n* Another cause of skin sclerosis (radiotherapy of the orofacial area…)\n* Periodontal specialized treatments, root and\u002For periodontal surgical treatment and\u002For subgingival instrumentation within the year before inclusion",{"count":388,"type":23},30,[26],"Systemic sclerosis (SSc) is a rare and complex autoimmune disease. Although its etiology remains unknown, various environmental factors, including certain microorganisms, can represent potential triggers of SSc in individuals with a permissive genetic background. Patients show a wide spectrum of clinical features including periodontitis, which is an inflammatory disease of the tooth-supporting tissues resulting from dysbiosis of the periodontal microbiota guided by inflammophilic bacteria.\n\nThe microbiota plays a fundamental role in the induction, training, and function of the host immune system. Numerous studies have highlighted the impact of an altered microbiota, i.e. dysbiosis, on the pathogenesis of immune-mediated diseases. Indeed, commensals are important to maintain immune homeostasis and changes in the microbial composition can be responsible for a loss of tolerance. SSc has been shown to be associated with gut dysbiosis and a depletion of commensals. However, although the oral cavity is one of the two largest microbial habitats, only one study (only focusing on Lactobacillus species) has investigated the oral microbiota in SSc. As periodontal dysbiosis is known to induce low-grade systemic inflammation and represents a risk factor for the development of various autoimmune diseases, the relationship between periodontal microbiota composition and SSc merits further exploration.\n\nThe aim of this pilot study is to characterize the taxonomic composition and metabolic pathways of the periodontal microbiota in SSc patients and age and sex-matched controls.",[392],"Scleroderma Systemic",{"date":117,"type":39},{"date":395,"type":39},"2024-10-24",{"date":397,"type":23},"2027-10-24",{"name":45,"class":46},{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":403,"acronym":404,"eligibilityCriteria":405,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":406,"targetDuration":4,"studyType":24,"phases":407,"briefSummary":408,"conditions":409,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":412,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":47},"100495975","evaluation-of-the-efficacy-and-safety-of-local-cryotherapy-treatment-of-recurrent-head-and-neck-cancer-in-irradiated-areas-a-pilot-study-100495975","NCT05738187","Evaluation of the Efficacy and Safety of Local Cryotherapy Treatment of Recurrent Head and Neck Cancer in Irradiated Areas: a Pilot Study","CRYORL","Inclusion Criteria:\n\n* Malignant head\u002Fneck tumor\n* Unresectable locoregional recurrence in a previously irradiated area\n* Contraindication to re-irradiation\n* Age \\> 18 years\n* Performance index ≤ 2 (WHO)\n* Life expectancy \\> 12 weeks\n* Absence of hemostasis disorders\n* Renal function: creatinine clearance ≥ 30 mL\u002Fmin by CKD-EPI method (Cockcroft-Gault formula or MDRD)\n* Subject affiliated to a social security health insurance plan\n* Subject able to understand the objectives and risks of the research and to give dated and signed informed consent\n* For a woman of childbearing age, negative blood pregnancy test at the inclusion visit\n\nExclusion Criteria:\n\n* Stage IV with distant metastases or multiple tumors\n* Melanoma, sarcoma, and lymphoma\n* Participants who have received chemotherapy or radiation therapy within 4 weeks\n* Other active cancer within the past 2 years (patients with carcinoma in situ, papillary thyroid carcinoma, basal cell skin carcinoma, localized Gleason 6 prostate cancer, or breast cancer in situ are allowed)\n* Concomitant therapy with any other systemic anticancer treatment\n* Contraindication of anaesthesiology character\n* Contraindication to MRI\n* Participation in another clinical study\n* Any social, medical or psychological condition that may prevent the patient from complying with the constraints of the protocol\n* Any significant pathology that may interfere with the patient's participation in the study\n* Subject under court protection\n* Subject under guardianship or curatorship\n* Pregnant or breastfeeding women",{"count":246,"type":23},[26],"In France, squamous cell carcinomas of the head and neck (SCCHN) are the 5th most common cancer. 60% of patients present with locally advanced tumors (stage III\u002FIV), characterized by a poor prognosis (5-year survival not exceeding 60%). The standard treatment consists of either surgical removal followed by adjuvant radiochemotherapy or exclusive radiochemotherapy.\n\nIn case of locoregional recurrence (about 40% of patients), salvage surgery can be proposed, allowing prolonged survival for less than one third of eligible patients. However, more than half of locoregional recurrences are unresectable. The standard treatment then consists of immunotherapy and\u002For chemotherapy for palliative purposes with a median survival of no more than 15 months. Stereotactic radiotherapy is another potentially curative option that allows a local control of 30-60% at 1 year, but at the cost of significant toxicity (up to 50% of grade 3-4 toxicities), thus limiting its indication.\n\nThe issue of salvage treatment also applies to other rarer histological forms, including naso-sinus and salivary gland tumors, for which the probability of overall survival at 5 years does not exceed 65% due to locoregional evolution, despite advances in surgical techniques and the addition of radiotherapy.\n\nDuring the last two decades, minimally invasive interventional radiology techniques have been developed in the field of oncology. Among these techniques, cryotherapy is now commonly used for the treatment of several cancers. The multiplication of its indications is based on numerous clinical advantages (good post-operative analgesia, good toxicity profile, good tumor control). Cryotherapy could thus be a therapeutic alternative in head and neck cancers in recurrence situation in irradiated and unresectable territory, allowing to maintain a curative project in a higher proportion of patients and also to have a more favorable toxicity profile than re-irradiation.",[410,411],"Recurrent Head and Neck Cancer","Local Cryotherapy Treatment",{"date":36,"type":39},{"date":414,"type":39},"2024-01-01",{"date":416,"type":23},"2028-05",{"name":45,"class":46},{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":422,"acronym":423,"eligibilityCriteria":424,"healthyVolunteers":12,"sex":18,"minAge":425,"maxAge":19,"enrollmentInfo":426,"targetDuration":4,"studyType":24,"phases":428,"briefSummary":429,"conditions":430,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":432,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":47},"100494225","assessment-of-light-therapy-in-insomnia-disorder-100494225","NCT05715411","Assessment of Light Therapy in Insomnia Disorder","InsomLum","Inclusion Criteria:\n\n* Patient aged 30 to 60 years\n* Insomnia disorders (ICSD-3) with sleep latency \\>30min - 3 times a week\n* Patient able to understand the objectives and risks associated with the research and to give informed dated and signed consent\n* Patient affiliated to a social health insurance scheme\n* For women of childbearing age, effective contraceptive measure for the duration of the research (hormonal contraception, IUD).\n\nExclusion Criteria:\n\n* \\- Shift work in the year preceding inclusion\n* Trans meridian travel (\\> 2 time zones) in the month preceding inclusion\n* Patient in exclusion period determined by a previous or ongoing study\n* Impossibility of giving the patient informed information (emergency patient, difficulty understanding the patient)\n* Patient under judicial protection\n* Patient under guardianship or curatorship\n* For a woman of childbearing age: ongoing pregnancy or breastfeeding\n* Drug treatment which can disturb sleep or the measurement of DLMO: corticosteroids by general route, beta-blockers in the evening, exogenous melatonin.\n* Phase delay syndrome defined according to the criteria of the international classification of ICSD-3\n* Restless legs syndrome with IRLS score\\> 20\n* Other psychiatric disorders or addictive disorder (screening with the MINI structured interview)\n* Other medical conditions not stabilized (detected by clinical interview), only the diseases appearing in the following list will constitute a criterion of non-inclusion:\n\n  * Chronic allergies\n  * Neurological disorders\n  * cardiovascular, respiratory, gastrointestinal, hematopoietic, visual diseases\n  * diseases of the immune system\n  * kidney and urinary tract diseases\n  * endocrine and metabolic diseases\n  * infectious diseases\n  * epilepsy","30 Years",{"count":427,"type":23},66,[26],"Sleep disorders represent a major public health issue and the leader in these disorders is insomnia with 10 to 15% of subjects in the general population reporting symptoms of insomnia with a daytime impact. In addition to being very common, insomnia leads to an increase in morbidity and mortality and weighs on healthcare systems worldwide. Despite this public health context, insomnia is underdiagnosed and rarely treated. Hypnotics have proven efficacy but with a risk of dependence and pharmacotolerance which appears within a few weeks. Cognitive behavioral therapy (CBT) has a good level of evidence and is now a benchmark treatment for the management of insomnia. Unfortunately, not all patients adhere to or respond to these procedures, which cannot be implemented for many of them either. There is therefore a need to identify other alternative therapeutic strategies, and we believe that exposure to light is a promising treatment.\n\nIn this perspective, it seems interesting to assess the effect of the propensity to fall asleep with an exposure to light therapy in patients suffering from insomnia.\n\nIn order to be in optimal ecological conditions, we want to use a portable light therapy device which allows easy, acceptable and ambulatory exposure.\n\nIf the lighttherapy is confirmed in insomnia under ecological conditions, this would make it possible to propose a new non-drug treatment, easy to access and on a large scale",[431],"Insomnia",{"date":36,"type":39},{"date":434,"type":39},"2024-11-28",{"date":436,"type":23},"2027-08",{"name":45,"class":46},{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":444,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":24,"phases":448,"briefSummary":449,"conditions":450,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":455,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":461},"100492933","compassion-for-psychiatric-disorders-and-self-stigma-100492933","NCT05698589","COMpassion for Psychiatric Disorders And Self-Stigma","Compassion Focused Therapy (CFT) for the Reduction of the Internalized Stigma of Mental Disorders: a Multi-center, Prospective, Randomized, Controlled Study","COMPASS","Inclusion Criteria:\n\n1. Patient ≥18 years of age\n2. Patient informed of the results of the preliminary medical examination\n3. Patient affiliated to a social health insurance plan (beneficiary or beneficiary's family)\n4. Patient with one or several diagnoses of chronic psychiatric disorder (schizophrenia, schizoaffective disorder, bipolar disorder, recurrent major depression, borderline personality disorder) or a neurodevelopmental disorder (autism spectrum disorder) treated as an outpatient or in a day hospital\n5. CGI-Severity score\\\u003C6 assessed by the psychiatrist (Berk et al., 2008) ISMI score indicating moderate to high self-stigma (\\>2.5; Lysaker et al., 2007)\n\n   Exclusion criteria:\n6. Patient in an exclusion period determined by a previous or ongoing study\n7. Patient participating in an interventional study involving psychotherapy or an experimental drug\n8. Patient in acute episode of their disorder according to the CGI Severity score\n9. Patient in a medical emergency or immediate life-threatening situation\n10. Patients with an intellectual disability (IQ\\\u003C70) estimated via the fNART (Mackinnon \\& Mulligan, 2005)\n\n12\\. Legal issues: care under constraint or patient deprived of freedom because of a judicial measure 13. Patient who does not speak and read French sufficiently",{"count":447,"type":23},336,[26],"People with mental disorders face frequent stigmatizing attitudes and behaviors from others . In response to this, they tend to isolate themselves, with the risk of impeding care and the process of recovery and integration into society . Stigmatization can also be assimilated by patients themselves - i.e. self-stigma. Self-stigma is involved in diminished coping skills that lead to social avoidance and difficulties in adhering to care . Reducing self-stigma and its emotional corollary, shame, is thus crucial to attenuate the disability associated with mental illness. Shame is inherent to self-stigma and leads to difficulties in adhering to care as well as greater severity of clinical presentations . Compassion Focused Therapy (CFT) is a third wave cognitive behavioral therapy that targets shame reduction and hostile self-to-self relationship and allows for symptom improvement while increasing self-compassion, a major resilience factor . Although shame is a prominent part of the concept of self-stigma, the efficacy of CFT has never been evaluated in individuals with high levels of self-stigma.\n\nIn this study, the investigators will evaluate the efficacy and acceptability of a group based CFT program on decreasing self-stigma, compared to treatment as usual (TAU) and a psychoeducation program whose efficacy has been assessed in a previous trial.",[451,452,453,319,454],"Bipolar Disorder","Schizophrenia","Depression","Autism Spectrum Disorder",{"date":117,"type":39},{"date":457,"type":39},"2023-04-03",{"date":459,"type":23},"2028-03-01",{"name":45,"class":46},7,{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":471,"conditions":472,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":474,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":47},"100457274","study-of-the-link-between-complement-activation-and-iga-nephropathy-severity-100457274","NCT05234463","Study of the Link Between Complement Activation and IgA Nephropathy Severity","ICONE","Inclusion Criteria:\n\n* Adult patients, male or female, with a biopsy proven IgA nephropathy.\n* Primitive and secondary forms can be included\n* Regardless of the date of diagnosis and the level of kidney function\n* With or without past of kidney transplantation\n* Followed in the Nephrology Department, Strasbourg University Hospital\n* Signed informed consent\n\nExclusion Criteria:\n\n* Active or recent infectious or inflammatory syndrome (\\\u003C2 months), recent vaccination (\\\u003C2 months), ongoing acute humoral rejection treatment, treatment with plasma exchanges (\\\u003C2 months), current treatment with complement inhibitors\n* Impossibility of giving informed information (emergency situation, difficulties in understanding, etc.)\n* Subject under safeguard of justice, guardianship or curatorship",{"count":470,"type":23},400,"ICONE study (IgA Complement and NEphropathy is a prospective monocentric observational study.\n\nThe main objective is to evaluate the relevance of complement activation as a biomarker of disease severity and progression in patients with a biopsy proven IgAN.",[473],"IgA Nephropathy Severity in Kidney Transplantation",{"date":117,"type":39},{"date":476,"type":39},"2022-05-09",{"date":478,"type":23},"2027-05-01",{"name":45,"class":46},{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":18,"minAge":488,"maxAge":489,"enrollmentInfo":490,"targetDuration":4,"studyType":24,"phases":492,"briefSummary":493,"conditions":494,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":498,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":7},"100453153","phase-2-pediatric-low-grade-glioma---mekinhibitor-trial-vs-chemotherapy-100453153","NCT05180825","Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy","A Randomized and Controlled Phase II Protocol in Non NF1 Pediatric and AYA (Adolescent and Young Adults) Patients Bearing a Newly Diagnosed Low Grade Glioma With Wild Type BRAF Gene Comparing a Daily Oral MEK Inhibitor (Trametinib) Versus Weekly Vinblastine for 18 Months","PLGG - MEKTRIC","Inclusion Criteria:\n\n* Age: ≥ 1 month to ≤ 25 years\n* Signed written informed consent prior to study participation of the legal representatives and the patient if the patient can understand the impact of clinical trial and to give consent. For patients above 18 years, their written informed consent will be obtained.\n* Patient may be under guardianship or curatorship (for patient under legal guardianship, authorization is given by the legal representative of the patient under guardianship. For patient under curatorship, consent will be obtained from the adult assisted by his or her legal curator\n* Histologically proven grade 1 glioma\u002Fmixed glio-neuronal tumors or pleomorphic xanthoastrocytoma (PXA) confirmed by local referee and the centrally pathology reviewing\n* Determination of a negative BRAFv600 mutation by immunohistochemistry and\u002For molecular methods\n* Systematic determination 7q34 duplication status or KIAA1549-BRAF fusion\n* Midline tumors without proven histone H3 mutations\n* Diffuse glioma without IDH1 mutation\n* Collection of fresh frozen tumor tissues and\u002For paraffin-embedded samples for further molecular biomarker testing\n* Sus-tentorial, optic pathway, midline and spine locations allowed\n* Karnofsky or Lansky ≥ 50%\n* Criteria for post-surgical treatment: severe visual or neurological symptoms at diagnosis, clinical deterioration of visual or neurological symptoms or radiological progression. The radiological progression is defined as an increase of solid part of the tumor of more than 25% compared to the pre-baseline MRI-imaging over a time period of at least 3 months or the occurrence of new metastatic lesions.\n* Infants below one year of age with chiasmatic and\u002For hypothalamic tumor will be treated immediately after surgery, independently from neurological and\u002For visual evolution\n* Females of child-bearing potential must be willing to practice highly effective contraception during all treatment and until 6 months after the last dose of study drugs' administration. Additionally, females of child-bearing potential must have a negative serum pregnancy test within 7 days prior to start of study drugs. Boys with reproductive potential must be willing to use condom and consider contraception for partner women of childbearing potential during treatment and until 4 months after the last study drugs' administration.\n* Patients must have adequate bone marrow function defined as: absolute neutrophil count (ANC) ≥ 1500\u002FµL; platelets ≥ 100,000\u002FµL and hemoglobin ≥ 9.0 g\u002Fdl\n* Patients must have adequate liver function within 7 days prior to screening: bilirubin (sum of unconjugated and conjugated) ≤ 1.5 ULN for age, ALT and AST ≤ 2.5 x upper limit of normal, alkaline phosphatase ≤ 4 x upper limit of normal, INR\u002FPTT \\\u003C 1.5 x upper limit of normal,\n* Patients must have adequate renal function within 7 days prior to screening: serum creatinine \\\u003C 1.5 x upper limit of normal for age and a creatinine clearance \\> 60 ml\u002Fmin for 1.73 m2\n* Cardiac function defined as a corrected QT (QTcF) interval \\\u003C 480 msec, LVEF ≥ lower limit of normal (LLN) by echocardiogram (ECHO)\n* Adequate blood pressure control (smaller or equal to the 95th percentile for patient's age, height and gender)\n* Patients are willing and able to comply with scheduled visits, treatment plan, laboratory tests and study procedures\n* Guardians (in case of patients under 18 years) or patient if above 18 years must be affiliated to or a beneficiary of health insurance system.\n\nNon-inclusion criteria\n\n* Patients presenting a neurofibromatosis type 1 (NF1) congenital disease\n* Pure optic nerve glioma, limited to one nerve and without optic chiasma infiltration.\n* Completely resected tumors\n* Previous treatment except tumor surgery\n* Pregnancy and lactation\n* Participation in other clinical trials\n* Prior non-surgical therapy for this tumor\n* Diffuse intrinsic pontine glioma (DIPG), even if histologically diagnosed as WHO grade II\n* Subependymal giant astrocytoma (SEGA) in patients with TSC\n* Patient having a known diagnosis of human immunodeficiency virus (HIV) infection, hepatitis B or C\n* Known hypersensitivity to drugs or excipients\n* History of another malignancy\n* History of current uncontrolled infection","1 Month","25 Years",{"count":491,"type":23},134,[182],"Pediatric low-grade glioma (PLGG) is a heterogeneous group of WHO grade I and II brain tumors, associated with a 10-year overall survival of 90%. It is the most common form of primary central nervous system (CNS) tumor arising during childhood, adolescence and young adulthood, accounting for over 30% of CNS tumors in this age group. A large group of PLGG patients will benefit from a complete resection of their tumor. Nevertheless, PLGG can occur anywhere and can be in some locations associated with neurological symptoms, unresectable or radiological progressive tumors that need medical treatments rapidly to avoid long-term sequelae. The current problem during this first line therapy is to improve tumor response, overall survival rate, as well as progression free survival. In our study, we will focus on a specific group of PLGGs without any congenital NF1 mutation and with a wild-type BRAF gene in the tumor. In this subgroup, for instance, the PFS is not increasing anymore above 50% at 3 years independently from the chemotherapeutic scheme. The two current standard therapies are carboplatin plus vincristine during 81 weeks or a weekly IV administration of vinblastine during 70 weeks. The most recent Canadian approach with vinblastine seems to have the same PFS rate, but with a better daily tolerance and less toxicities than the carboplatin\u002Fvincristine combination. Therefore, it is becoming the new standard approach in those patients. Nevertheless, we need to improve more their outcome with less recurs and a better first-line tumor response. The recent molecular discoveries involving the Ras\u002Fmitogen-activated protein kinase pathway in those PLGG is opening a new era with specific targeted therapies that might be the key to improve their survivals and giving hope to less treatment lines and a better tumor response. Therefore, we designed a prospective open randomized phase II study, named PLGG-MEKTRIC, comparing the experimental arm (a daily MEK inhibitor, Trametinib, Mekinist©) to a standard arm comprising weekly vinblastine during 18 courses of 4 weeks each. The study will enroll 134 patients with a PLGG during childhood, adolescence or young adulthood with no NF1-related disease and without any BRAFv600 mutation located in brain or spine. 67 patients, in each treatment arm, are planned to be enrolled to answer our primary objective. This primary objective will be to determine in the experimental arm a 20% superiority of the 3-year PFS rate in comparison with the standard treatment administered during 18 courses (e.g. 72 weeks). A stratification of the patients will be done in both arms based on molecular tumor results and brain\u002Fspine locations to obtain two equivalent arms to be analyzed.\n\nThe recruitment time will be 36 months and the complete follow-up of each patient will last 3 years. The secondary objectives will be in both arms: the tumor response rate at 24 and 72 weeks of treatment, the 3-year PFS and OS rates and the frequency of AE\u002FSAE\u002FSUSAR (Adverse Event\u002FSerious Adverse Event) based on CTCAE criteria during the 3 years after the first administration. A Quality of Life (QoL) assessment, based on PEDsQL questionnaires, at 24 weeks, at the end of treatment and 3 years after 1st treatment administration in both arms will be part of this study. Finally, 3-year PFS and OS will be analyzed according to molecular biomarkers and visual assessment (LogMar scale) in each arm. An economic analysis is also planned as an ancillary study to determine a cost effectiveness of the best arm and complementary ancillary molecular studies are already organized. In the future, we hope to push forward this new-targeted therapy as a referenced first line treatment of pediatric PLGG to obtain the best tolerance and positive long-term impact and to extend our knowledge of MEK inhibitor impact in molecular subgroups and in optical pathway locations. We also plan to do a \"switch\" strategy in patients relapsing in standard arm and we will propose systematically to those patients the experimental treatment (MEK inhibitor ).",[495,496,497],"Grade 1 Glioma","Mixed Glio-neuronal Tumors","Pleomorphic Xanthoastrocytoma",{"date":36,"type":39},{"date":500,"type":39},"2022-05-05",{"date":502,"type":23},"2031-12-01",{"name":45,"class":46},{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":508,"acronym":509,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":18,"minAge":511,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":24,"phases":514,"briefSummary":515,"conditions":516,"keywords":519,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":525,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":47},"100449907","personalized-repetitive-transcranial-magnetic-stimulation-rtms-in-cognitive-fluctuations-of-dementia-with-lewy-bodies-dlb-proof-of-concept-100449907","NCT05138588","Personalized Repetitive Transcranial Magnetic Stimulation (rTMS) in Cognitive Fluctuations of Dementia With Lewy Bodies (DLB): Proof of Concept","STIMLEWY","Inclusion Criteria:\n\n* Male or female patient aged ≥ 45 years\n* Enrolled in a social health insurance scheme\n* Diagnosed with probable DLB according to McKeith et al. criteria, 2017, or McKeith et al. 2020 criteria for the prodromal stage\n* A Mini Mental State Examination (MMSE; Folstein et al., 1983) score ≥ to 18 in the last 6 months (prodromal stage or a major neurocognitive disorder (dementia syndrome) at moderate stage)\n* MMSE score ≥ to 15 at the inclusion visit\n* Presence of clinically significant cognitive fluctuations\n* Caregivers of eligible patients do have to be able to stay with the patient for at least 4 hours a day, 3 days a week, and have to be able to provide requested information and accompany the patient to the certain visits.\n* The patient must be able to understand the objectives and risks of the study and has to be able to give dated and signed informed consent. In the case of a designed guardian or curator, the guardian or curator will sign the consent.\n* For women of childbearing age, effective contraception throughout the study is required\n\nExclusion criteria:\n\n* History of generalized seizures (epilepsy)\n* Pharmacological treatment for cognitive fluctuations in DLB with dose modifications that have taken place less than 2 months before the first visit of the protocol (anticholinesterase and neuroleptics)\n* Anti-epileptic drug treatment \"Keppra\" (Levetiracetam)\n* History of psychosis or severe depression unrelated to DLB\n* History of brain surgery (tumour removal, electrode implantation, certain strokes as judged by the investigator, oedema...)\n* Patients with any contraindication for MRI scans (claustrophobia, pacemaker, cochlear implant, mechanical heart valve, metallic prostheses, neurostimulators, other non-removably implanted electronic medical devices etc.)\n* Subject unable to understand the aims and risks of the study and patients unable to give full informed consent\n* Having a MMSE score \\\u003C to 18 in the last 6 months (prodromal stage or mild to moderate dementia)\n* MMSE score \\\u003C to 15 at the inclusion visit\n* Patients in an emergency or life-threatening situation\n* Patients under court protection\n* Pregnancy\n* Breastfeeding\n* Patients in exclusion period (determined by a previous or current study)","45 Years",{"count":513,"type":23},40,[26],"The present study is a monocentric, therapeutic clinical trial involving forty patients diagnosed with Dementia with Lewy Bodies (DLB). The aim of this clinical trial is to evaluate the feasibility and relevance of repetitive transcranial magnetic stimulation (rTMS); a non-invasive neuromodulation technique, with a main emphasis on the evaluation of the outcome on cognitive fluctuations. For this purpose, we will compare two distinct rTMS conditions (control and experimental) in a pre-post rTMS setting. The experimental condition will be targeting the insular cortex which has been shown to be affected at prodromal DLB stages, in the form of decreased grey matter concentration and a decreased regional Cerebral Blood Flow (rCBF hypoperfusion) \\[Blanc et al., 2015 ; Roquet et al., 2016 ; Roquet et al., 2017\\]. Furthermore, these insular alterations are correlated to cognitive fluctuations \\[Chabran et al., 2020\\]. In DLB, cognitive fluctuations are particularly pervasive and manifest in the form of alertness alterations and modifications of arousal states. Participants will repeatedly undergo a series of clinical and cognitive assessments in addition to several neuroimaging examinations, namely multimodal Magnetic Resonance Imaging (MRI) and electroencephalogram (EEG) recordings, in order to evaluate potential physiological modifications and clinical changes of symptoms, pre-\u002Fpost-rTMS.",[517,518],"Dementia With Lewy Bodies Diagnosis","Significant Cognitive Fluctuations in DLB",[520,521,522,523,524],"rTMS","arousal","DLB","fluctuations","insula",{"date":36,"type":39},{"date":527,"type":39},"2022-02-02",{"date":529,"type":23},"2028-07",{"name":45,"class":46},{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":539,"targetDuration":4,"studyType":24,"phases":541,"briefSummary":542,"conditions":543,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":545,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":47},"100432916","compression-ultrasonography-in-non-high-probability-of-deep-vein-thrombosis-100432916","NCT04917328","Compression Ultrasonography in Non-high Probability of Deep Vein Thrombosis","Evaluation of the Predictive Value of Compression Venous Ultrasound by the Emergency Physician for Excluding the Diagnosis of Proximal Deep Vein Thrombosis (DVT) in Patients With Non-high Clinical Pretest Probability","EPREVUP","Inclusion Criteria:\n\n* adult patient\n* Patient presenting to the emergency department with clinical suspicion of DVT (i.e. pain and\u002For lower extremity edema).\n* Patient with a non-high probability according to the modified Wells score, i.e. a score of 0 or 1\n* Subject with a social health insurance plan\n* Subject able to understand the objectives and risks of the research and to give a signed and dated informed consent\n\nExclusion Criteria:\n\n* Patient with suspected pulmonary embolism\n* Patient with a high probability of DVT\n* Impossible to perform a whole leg doppler ultrasound within 5 days\n* Pregnant or breast-feeding woman, on patient's declaration\n* Subject under court protection\n* Subject under guardianship or curatorship",{"count":540,"type":23},700,[26],"Compression ultrasound is commonly used in emergency department. Accuracy to rule out deep vein thrombosis is excellent but lower then Ddimer assessment which is actually gold standard. With progress in formation of emergency physicians (EP), quality of material used, the investigators hypothesize that compression ultrasound can rule out deep vein thrombosis in case of non high probability, as standard care and DDimer assay.",[544],"Deep Vein Thrombosis",{"date":117,"type":39},{"date":547,"type":39},"2022-02-21",{"date":549,"type":23},"2028-02-28",{"name":45,"class":46},{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":556,"acronym":557,"eligibilityCriteria":558,"healthyVolunteers":77,"sex":18,"minAge":56,"maxAge":19,"enrollmentInfo":559,"targetDuration":4,"studyType":24,"phases":561,"briefSummary":562,"conditions":563,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":565,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":569,"locationsCount":47},"100420627","multidimensional-apathy-in-psychiatric-pathologies-100420627","NCT04757220","Multidimensional Apathy in Psychiatric Pathologies.","Cognitive and Neural Mechanisms of Multidimensional Apathy in Psychiatric Pathologies","AmSeD","Inclusion Criteria:\n\n* Inclusion criteria (all subjects):\n* age between 18 and 60 years\n* men or women volunteers, hospitalized or not\n* subject affiliated to an health insurance\n* subject having signed an informed consent\n\nInclusion criteria (for schizophrenic patients):\n\n\\- presence of DSM-V TR criteria for schizophrenia (American Psychiatric Association, 1994)\n\nInclusion criteria (for depressive patients):\n\n\\- presence of DSM-V TR criteria for depression (American Psychiatric Association, 1994)\n\nExclusion Criteria:\n\n* a major or non stabilized somatic disorder\n* medical history likely to affect cerebral anatomy or linked to an abnormality (neonatal distress, neurochirurgical intervention, neurological disorders, stroke attack)\n* any disorders involved in the use of a psycho-active substance (as defined by the DSM-IV)\n* sensory disabling impairments, and specifically visual acuity \\\u003C 8\n* general anaesthesia during the 3 months before the study\n* pregnancy (declared by the subject)\n* persons in an emergency situation\n* persons deprived in any way of their liberty\n* persons in period of exclusion in an other protocol\n\nExclusion criteria (for controls):\n\n\\- use of psychotropic substance during the 3 weeks before the study\n\nExclusion criteria (for patients):\n\n\\- use of benzodiazepines",{"count":560,"type":23},144,[26],"Apathy is defined by quantitative decrease in goal-directed activity in comparison to the person's previous level of functioning. Apathy is a transnosographic symptom, prevalent in many neurological and psychiatric pathologies (specifically in schizophrenia and depression), and almost half of patients suffer from it. It is an important source of burden, affecting both personal and occupational life. Despite its high prevalence and negative consequences, no pharmacological or non-pharmacological treatments exist, the underlying mechanisms of apathy being poorly understood. The main aim of the present study is to advance in our knowledge of cognitive and neural mechanisms of apathy by using a multidimensional model of apathy, distinguishing three forms: executive, emotional and auto-activation\u002Finitiative.\n\nthe investigators hypothesize, independently of the pathology (schizophrenia and depression), the existence of different cognitive deficits underlying each of the 3 subforms of apathy. Indeed, according to the predictions of Levy and Dubois' model (2006), executive disorders underlie the cognitive form of apathy. It may be related to lesions of the dorsolateral prefrontal cortex and the cognitive territory of the basal ganglia. Emotional apathy could be due to motivational disorder. Dysfunctions or lesions in the orbital and medial prefrontal cortex and limbic territories of the basal ganglia may underlie this. Finally, the initiative form, may be a mixed form, with both motivational and executive difficulties. Lesions or dysfunctions may affect both the cognitive and limbic territories of the basal ganglia or the anterior cingulate cortex.",[564],"Apathy",{"date":117,"type":39},{"date":567,"type":39},"2022-01-05",{"date":43,"type":23},{"name":45,"class":46},{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":4,"eligibilityCriteria":576,"healthyVolunteers":77,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":577,"targetDuration":4,"studyType":24,"phases":579,"briefSummary":580,"conditions":581,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":586,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":47},"100348068","photomotor-reflex-to-evaluate-the-role-of-the-non-visual-effects-of-light-in-neurological-psychiatric-and-ophthalmological-pathologies-100348068","NCT03811964","Photomotor Reflex to Evaluate the Role of the Non-visual Effects of Light in Neurological, Psychiatric and Ophthalmological Pathologies","Study of the Photomotor Reflex to Evaluate the Role of the Non-visual Effects of Light in Neurological, Psychiatric and Ophthalmological Pathologies","Inclusion Criteria:\n\n* Man or woman\n* Aged 18 years or older\n* Subject having signed a free and informed consent\n* Subject affiliated to a social protection scheme Arm 1 :Subjects with primary sleep-wake disorder Arm 2 : subjects presenting a neurological pathology with disorder of the controls of the wake and the sleep Arm 3 : subject presenting a psychiatric pathology pathology with disorder of the controls of the wake and the sleep Arm 4 : subject presenting an ophthalmological pathology with possible alteration of the photoreception and \u002F or phototransduction Arm 5 : subjects with photosensitivity with regulation disorder of sleep and wake Arm 6 : healthy subject\n\nExclusion Criteria:\n\nAge-Related Macular Degeneration (AMD) and all maculopathies (retinopathies pigmentosa, macular involvement of diabetes)\n\n* Cataract with significant vision loss \\\u003C5\u002F10\n* Chorioretinal neovascularization\n* Subject in exclusion period determined by previous or current study\n* Impossibility to give the subject information enlightened (subject in emergency situation, difficulties of understanding the subject, ...)\n* Subject under the protection of justice\n* Subject under guardianship or curatorship\n* Pregnancy \u002F Breastfeeding",{"count":578,"type":23},726,[26],"The light has visual and non-visual effects on organism and can act on the behavior, the mood, the cognition and the sleep. These effects are mediated by \"classical\" retina photoreceptors which allow vision (rods, cones) but also melanopsin cells. The non-visual effects of light seems to be altered in many neurological, psychiatric or ophtalmological conditions but their exact role in the pathogenesis remains poorly understand. The purpose of the study is to increase our knowledge of the non-visual effects of light and establish new therapeutic applications",[582,583,584,585],"Sleep Disorders","Neurological Pathologies","Psychiatric Pathologies","Ophthalmological Pathologies",{"date":36,"type":39},{"date":588,"type":39},"2020-01-22",{"date":590,"type":23},"2028-02",{"name":45,"class":46},""]